Nektar Therapeutics (NKTR) P/E Ratio History
Historical price-to-earnings valuation from 2015 to 2019
Loading P/E history...
NKTR Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Nektar Therapeutics (NKTR) trades at a price-to-earnings ratio of -8.6x, with a stock price of $83.37 and trailing twelve-month earnings per share of $-8.08.
The current P/E is 110% below its 5-year average of 87.6x. Over the past five years, NKTR's P/E has ranged from a low of 9.1x to a high of 417.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, NKTR trades at a 138% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, NKTR trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NKTR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NKTR P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 25.5 | 1.11 | -25% | |
| $39B | 127.0 | - | +207% | |
| $12B | 16.6 | 0.32Best | +58% | |
| $20B | 15.3Lowest | - | +4173%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
NKTR Historical P/E Data (2015–2019)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2019 Q1 | Sun Mar 31 2019 00:00:00 GM | $504.00 | $52.80 | 9.5x | -89% |
| FY2018 Q4 | Mon Dec 31 2018 00:00:00 GM | $493.05 | $54.00 | 9.1x | -90% |
| FY2018 Q3 | Sun Sep 30 2018 00:00:00 GM | $914.40 | $59.40 | 15.4x | -82% |
| FY2018 Q2 | Sat Jun 30 2018 00:00:00 GM | $732.45 | $73.35 | 10.0x | -89% |
| FY2015 Q2 | $187.65 | $0.45 | 417.0x | +376% | |
| FY2015 Q1 | $165.00 | $2.55 | 64.7x | -26% |
Average P/E for displayed period: 87.6x
See NKTR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NKTR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NKTR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNKTR — Frequently Asked Questions
Quick answers to the most common questions about buying NKTR stock.
Is NKTR stock overvalued or undervalued?
NKTR trades at -8.6x P/E, below its 5-year average of 87.6x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does NKTR's valuation compare to peers?
Nektar Therapeutics P/E of -8.6x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is NKTR's PEG ratio?
NKTR PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2015-2019.